**Allergan – Call for Grants Notification**  
**Issue Date:** January 27, 2017  
**Therapeutic Area:** Schizophrenia

**Purpose:** Allergan is interested in providing grant support for independent continuing professional development and education of healthcare professionals in the United States who treat patients with schizophrenia. This Call for Grants Notification (CFG) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Allergan Medical Education is committed to supporting independent educational activities in specific therapeutic areas that foster increased understanding of scientific, clinical or healthcare issues, and that serve to improve patient care. All grants are awarded at Allergan’s sole discretion. Approval of grant funding is never related to or conditioned upon past prescriptions or purchases of Allergan products. Furthermore, Allergan does not offer or provide educational grants to encourage or to reward the prescription, purchase, ordering, or recommending of Allergan products.

**Intended Audience**
- Psychiatrists

**Educational Design**
- Live Symposium with a start date in May or June 2017
- Enduring materials inclusive of accredited online material and/or print supplement

**Application Title:** “CFG SCZ 09— Program Title”
- Your grant title must begin with the Call for Grants ID number
- Refer to the submission instructions for further guidance on submitting your grant application

<table>
<thead>
<tr>
<th>Submission Timeframe</th>
<th>January 28, 2017 – March 3, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposal</td>
<td>Live Symposium with a start date in May or June 2017</td>
</tr>
<tr>
<td>Program Format</td>
<td>Live symposium with enduring materials/print accredited supplements</td>
</tr>
<tr>
<td>Program Cost</td>
<td>≤$250,000</td>
</tr>
</tbody>
</table>

**Eligibility Criteria**
- Applicants must be US-based, registered on Allergan’s Grant Management website at www.allerganmededgrants.com, and in good standing and accredited to provide CME/CE by an official accrediting agency (e.g. ACCME, AOA, AAFP, AMA, ADA CERP, ANCC, ACPE, etc.).
- Our grant application system requires the registration of accredited providers and third parties before a grant application can be submitted.
- We recommend that your organization register in the system before the deadline if you are not currently registered.

**Educational Needs**
Schizophrenia is characterized as a chronic psychiatric disorder in which an effected patient has abnormalities in their perception of reality. Onset of symptoms typically occurs in young adulthood (between ages of 16 and 30) and is estimated to effect 0.4-1% of the population. This mental illness inflicts burden on patients through its positive and negative symptoms. Positive symptoms include paranoid/bizarre delusions, auditory and visual hallucinations, disorganized train of thought, and unusual speech or movement. Negative symptoms include “flat”
affect, lack of motivation, anhedonia, and reduced social drive. The etiology of the disease is largely attributed to an imbalance of dopamine, a neurotransmitter, and excessive binding of dopamine to receptors.2

While current treatments aim to control impulsivity, aggression, and psychosis in schizophrenia, there is unmet need in the control of the negative symptoms that inflict burden on the patient. Pharmacological agents available to treat schizophrenia can also be limited by side effect profiles, including unwanted extrapyramidal symptoms, weight gain, etc. New pharmacological agents are emerging aiming to treat the positive, negative, affective, and cognitive symptoms of schizophrenia.3, 4

Many of these new pharmacological agents are partial agonists at the dopamine receptors. Recent findings have lead to a shift in the focus on the D2 and D3 receptors and their potential roles in psychiatric conditions. D3 receptors are selectively-distributed and highly dense in both the mesolimbic system, which is associated with emotion and memory, and the ventral striatum, a crucial area in the pathology of mental illnesses. The selective targeting of the D2/D3 receptors has been an active area of research in the efforts to identify targets for novel antipsychotic drugs that can better treat psychiatric patients and relieve the burden of their symptoms on both the patients and their caregivers.5, 6

Based on the high prevalence of schizophrenia and need for novel antipsychotic drug use in these populations, there is an educational need to improve understanding of the negative symptoms of schizophrenia and receptor pharmacology, specifically focusing on the D3 receptor as a treatment target.

Based on the gaps documented in the literature, funding is available to support independent certified educational activities developed by accredited providers that address gaps in the understanding of negative symptoms and receptor pharmacology in schizophrenia.

We request that educational providers independently assess whether an educational need exists to improve management of patients with schizophrenia as well as demonstrate that the proposed educational intervention(s) is needed to address knowledge, performance, and/or practice gaps among the target audience of healthcare providers.

Proposed and implemented educational activities must be fully compliant with all applicable accrediting organization and industry standards, guidelines, and requirements as they apply to the conduct of independent medical education. If an accredited provider chooses to submit an educational grant request in response to this request for proposal, a complete and independent needs assessment including identified barriers to patient care, must be provided with the grant application.

Outcomes Measurement
Applications should include a detailed plan to provide quantitative evidence to show that the educational initiative had impact on healthcare provider knowledge, competence and/or performance outcomes (Moore level 3 - 5).7 The proposal should include pre- and post-educational assessments or a comparison to a control group who has not been exposed to the intervention. A description of the methodology used to evaluate the reach and quality of the activity should be provided.

Submission Instructions
Submit applications through Allergan’s Grant Management website at www.allerganmededgrants.com.

When submitting the application, please ensure the following are completed:
1. Select Schizophrenia/Bipolar Mania – CFG ONLY as the therapeutic area
2. Include the following, “CFG SCZ 09” in the program title of the grant application
6. Complete all sections of the grant application
7. Upload all documents requested by the system

**Deadline for Submission of Application**
March 3, 2017

**Decision Date and Notification**
You will receive an acknowledgement email once the Allergan Medical Education Department has reviewed your completed grant application approximately the **fourth week of March, 2017.** After your request has been completely reviewed by Allergan’s Grant Review Committee, Allergan will provide you a written response regarding your request. If your request is approved, the response will be accompanied by a Letter of Agreement, which must be signed and returned to the Allergan Medical Education Department. Please do not consider any request approved until you have received written documentation from the Allergan Medical Education Department stating that your grant request has been approved.

**Terms and Conditions**
We reserve the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CFG. Allergan is not responsible for any costs associated with a CFG application.

**Transparency**
The Allergan grant approval process is in full accordance with the recommendations and the guidance of the Office of Inspector General (OIG), Pharmaceutical Research and Manufacturers of America (PhRMA), Advanced Medical Technology Association (AdvaMed), the Accreditation Council for Continuing Medical Education (ACCM), “National Physician Payment Transparency Program: OPEN PAYMENTS” commonly known as the “Sunshine Act,” and internal Allergan Compliance policies.

Allergan, at its sole discretion, has the right to disclose the details of funded independent medical education activities, including those that may be required by federal, state, and/or local laws and regulations. This disclosure may include, but shall not be limited to, details of the activity and the grant amount.

**References**